Current Report Filing (8-k)
December 02 2021 - 6:14AM
Edgar (US Regulatory)
0001053369
false
0001053369
2021-12-02
2021-12-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
December
2, 2021
Date
of Report (Date of earliest event reported)
ELITE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
165
Ludlow Avenue, Northvale, New Jersey 07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
ELTP
|
|
OTCQB
|
Item
1.01 Entry Into A Material Definitive Agreement
On
October 18, 2021 Elite Pharmaceuticals Inc. (“Elite”) , renewed its License, Supply, and Distribution Agreement with Lannett
Company, Inc. (“Lannett”) to market two Elite generic products in the United States. Lannett will continue to be the exclusive
U.S. distributor for the two generic products that Elite and Mikah Pharma co-own. This First Renewal Term shall be from March 22, 2022
until March 5, 2024.
The
first product is a generic version of Adderall®, an immediate-release mixed
salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate,
Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg tablets. The
second product is a generic version of Adderall
XR®, an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate,
Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg tablets.
Under
the Agreement, Lannett will provide sales, marketing, and distribution for the products, and Elite will manufacture the product. Lannett,
Elite, and Mikah will each receive a share of the profits.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
|
Description
|
104
|
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
December 2, 2021
|
ELITE
PHARMACEUTICALS, INC.
|
|
By:
|
/s/
Nasrat Hakim
|
|
|
Nasrat
Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024